Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
AEON Clinic in Dubai offers physician-supervised IV nutrient therapies and NAD+ treatments as part of a broader shift toward personalized health optimization focused on healthspan rather than lifespan. The clinic positions these interventions within longer-term health strategies rather than as standalone wellness experiences, reflecting emerging sophistication in how longevity medicine is being integrated into clinical practice.
Elecoglipron (AZD5004/ECC5004), an oral once-daily GLP-1 receptor agonist developed by Eccogene and AstraZeneca, will present Phase 1b and Phase 2b clinical trial data at the American Diabetes Association Scientific Sessions in June 2026. The candidate targets weight loss and type 2 diabetes management with the practical advantage of no food or water restrictions.
Augustine Therapeutics will present preclinical data on an HDAC6 inhibitor for heart failure with preserved ejection fraction at the American Diabetes Association conference. The selective HDAC6 inhibitor represents a mechanistic approach to a prevalent cardiometabolic phenotype where ejection fraction remains normal despite functional impairment.
HeartSciences launched MyoVista Insights 1.3 with an AI-ECG Algorithm Marketplace, integrating FDA-cleared algorithms like Bunkerhill Health's ejection fraction detector into a cloud-native platform accessible to primary care through large health systems. This infrastructure democratizes advanced cardiac signal interpretation across clinical settings and establishes a scalable commercial model for third-party algorithm deployment.
Handgrip strength significantly moderates the relationship between depression and cancer risk in adults over 50, with stronger grip associated with reduced cancer incidence across multiple cancer types. This finding suggests that neuromuscular capacity functions as a protective factor against the compounding effects of depression on malignant disease.
Grip strength correlates strongly with longevity and serves as a marker of systemic health—muscle function, cardiovascular integrity, metabolic capacity—but does not itself drive longer life. The confusion between correlation and causation has led wellness influencers to oversell grip training as a direct longevity intervention when it is, in fact, a measurable signal of underlying physiological robustness.
Scribe Therapeutics has gained regulatory clearance to test STX-1150, a CRISPR-based therapy designed to suppress the PCSK9 gene in the liver and achieve durable LDL cholesterol reduction from a single treatment. This approach addresses a critical adherence gap: most people struggle to maintain lifelong cholesterol medication, creating a window of unprotected cardiovascular risk that conventional drugs fail to close.
Fractyl Health has initiated the first human trial of RJVA-001, a gene therapy designed to enable the pancreas to produce GLP-1 endogenously rather than requiring chronic external dosing. This approach represents a fundamental shift in metabolic medicine from lifelong symptom management toward potential restoration of underlying physiological function.
The Thalion Initiative, a newly launched nonprofit backed by prominent geroscience advisors, aims to fund fundamental aging research across five interconnected areas with a decade-long strategic plan. The organization represents a deliberate pivot from fragmented funding models toward coordinated, long-term investigation of aging biology itself.
HAYA Therapeutics has initiated Phase 1 dosing of HTX-001, an antisense oligonucleotide targeting WISPER RNA to reprogram cardiac fibroblasts and reduce pathological fibrosis in heart failure. Preclinical data support reductions in cardiac fibrosis and functional improvements, with the trial progressing from healthy volunteers to patients with nonobstructive hypertrophic cardiomyopathy.
CellProthera is advancing ProtheraCytes, a CD34+ stem cell therapy, toward Phase 3 trials in post-infarction patients with the goal of preventing progression to heart failure. The approach delivers cells directly to the scar border zone via catheter, potentially offering earlier myocardial tissue repair than existing pharmacological or device-based interventions.
Kailera Therapeutics is advancing ribupatide injection (KAI-9531), a once-weekly GLP-1/GIP dual agonist in Phase 3 trials for obesity treatment, with company leadership presenting clinical updates at the June 2026 Jefferies conference. The candidate represents one of several GLP-1-based mechanisms in development aimed at addressing weight regulation across different patient populations and delivery preferences.